BEIGENE(688235.SH): It is expected to achieve positive operating profit for the full year of 2025.

BEIGENE (688235.SH) announced that the company participated in the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 (US Eastern Time) and presented their report. The CEO, Mr. John Doe, introduced the recent business situation, the company's pipeline layout in the fields of blood tumors and solid tumors, as well as future development plans and expected progress. He also mentioned that according to the US Generally Accepted Accounting Principles, the company expects to achieve a positive operating profit for the full year of 2025 (i.e. operating income greater than the sum of operating costs, sales expenses, administrative expenses, and research and development expenses).